Videos

Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.

Alexander Olawaiye, MD, discusses final overall survival results from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Lyudmila Bazhenova, MD, discusses updated results from the TRUST-I and TRUST-II trials assessing taletrectinib in TKI-naive patients with ROS1-positive non-small cell lung cancer.

Francesca Jackson-Spence, MBChB, discusses final results from the phase 2 CALYPSO study evaluating savolitinib plus durvalumab in metastatic papillary renal cell carcinoma.

Jacqueline Barrientos, MD, discusses emerging combination treatment strategies in chronic lymphocytic leukemia.

Alison Schram, MD, discusses results from the phase 2 PYNNACLE trial which assessed rezatapopt in TP53 Y220C mutated advanced or metastatic ovarian cancer.

Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.

Brian Slomovitz, MD, discusses results from the ROSELA trial which led to the recent FDA approval of relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.

Catherine Haring, MD, discusses findings from a study evaluating ctDNA as a biomarker in patients with HPV-related oropharyngeal cancer undergoing surgery.